|
1
|
Gibbs ZA and Whitehurst AW: Emerging
contributions of cancer/testis antigens to neoplastic behaviors.
Trends Cancer. 4:701–712. 2018.
|
|
2
|
Saxena M, van der Burg SH, Melief CJM and
Bhardwaj N: Therapeutic cancer vaccines. Nat Rev Cancer.
21:360–378. 2021.
|
|
3
|
Florke Gee RR, Chen H, Lee AK, Daly CA,
Wilander BA, Fon Tacer K and Potts PR: Emerging roles of the MAGE
protein family in stress response pathways. J Biol Chem.
295:16121–16155. 2020.
|
|
4
|
Lian Y, Meng L, Ding P and Sang M:
Epigenetic regulation of MAGE family in human cancer
progression-DNA methylation, histone modification, and non-coding
RNAs. Clin Epigenetics. 10:1152018.
|
|
5
|
Marchand M, van Baren N, Weynants P,
Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F,
Humblet Y, et al: Tumor regressions observed in patients with
metastatic melanoma treated with an antigenic peptide encoded by
gene MAGE-3 and presented by HLA-A1. Int J Cancer. 80:219–230.
1999.
|
|
6
|
Parvizpour S, Razmara J, Pourseif MM and
Omidi Y: In silico design of a triple-negative breast cancer
vaccine by targeting cancer testis antigens. Bioimpacts. 9:45–56.
2019.
|
|
7
|
Vansteenkiste JF, Cho BC, Vanakesa T, De
Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J,
Nakayama H, et al: Efficacy of the MAGE-A3 cancer immunotherapeutic
as adjuvant therapy in patients with resected MAGE-A3-positive
non-small-cell lung cancer (MAGRIT): A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol. 17:822–835.
2016.
|
|
8
|
Miao L, Zhang Y and Huang L: mRNA vaccine
for cancer immunotherapy. Mol Cancer. 20:412021.
|
|
9
|
Sahin U and Türeci O: Personalized
vaccines for cancer immunotherapy. Science. 359:1355–1360.
2018.
|
|
10
|
Chen F, Wang Y, Gao J, Saeed M, Li T, Wang
W and Yu H: Nanobiomaterial-based vaccination immunotherapy of
cancer. Biomaterials. 270:1207092021.
|
|
11
|
Polla Ravi S, Shamiya Y, Chakraborty A,
Elias C and Paul A: Biomaterials, biological molecules, and
polymers in developing vaccines. Trends Pharmacol Sci. 42:813–828.
2021.
|
|
12
|
Xiao L, Huang Y, Yang Y, Miao Z, Zhu J,
Zhong M, Feng C, Tang W, Zhou J, Wang L, et al: Biomimetic
cytomembrane nanovaccines prevent breast cancer development in the
long term. Nanoscale. 13:3594–3601. 2021.
|
|
13
|
Verma P, Biswas S, Yadav N, Khatri A,
Siddiqui H, Panda JJ, Rawat BS, Tailor P and Chauhan VS: Delivery
of a cancer-testis antigen-derived peptide using conformationally
restricted dipeptide-based self-assembled nanotubes. Mol Pharm.
18:3832–3842. 2021.
|
|
14
|
Huang W, Zhang Q, Li W, Yuan M, Zhou J,
Hua L, Chen Y, Ye C and Ma Y: Development of novel nanoantibiotics
using an outer membrane vesicle-based drug efflux mechanism. J
Control Release. 317:1–22. 2020.
|
|
15
|
Jian W, Li X, Kang J, Lei Y, Bai Y and Xue
Y: Antitumor effect of recombinant Mycobacterium smegmatis
expressing MAGEA3 and SSX2 fusion proteins. Exp Ther Med.
16:2160–2166. 2018.
|
|
16
|
Sebastian M, Schröder A, Scheel B, Hong
HS, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M,
Atanackovic D, et al: A phase I/IIa study of the mRNA-based cancer
immunotherapy CV9201 in patients with stage IIIB/IV non-small cell
lung cancer. Cancer Immunol Immunother. 68:799–812. 2019.
|
|
17
|
Neek M, Tucker JA, Kim TI, Molino NM,
Nelson EL and Wang SW: Co-delivery of human cancer-testis antigens
with adjuvant in protein nanoparticles induces higher cell-mediated
immune responses. Biomaterials. 156:194–203. 2018.
|
|
18
|
van der Bruggen P, Traversari C, Chomez P,
Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene
encoding an antigen recognized by cytolytic T lymphocytes on a
human melanoma. J Immunol. 178:2617–2621. 2007.
|
|
19
|
van der Bruggen P, Traversari C, Chomez P,
Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene
encoding an antigen recognized by cytolytic T lymphocytes on a
human melanoma. Science. 254:1643–1647. 1991.
|
|
20
|
Chomez P, De Backer O, Bertrand M, De
Plaen E, Boon T and Lucas S: An overview of the MAGE gene family
with the identification of all human members of the family. Cancer
Res. 61:5544–5551. 2001.
|
|
21
|
Barker PA and Salehi A: The MAGE proteins:
Emerging roles in cell cycle progression, apoptosis, and
neurogenetic disease. J Neurosci Res. 67:705–712. 2002.
|
|
22
|
Lee AK and Potts PR: A comprehensive guide
to the MAGE family of ubiquitin ligases. J Mol Biol. 429:1114–1142.
2017.
|
|
23
|
Simpson AJG, Caballero OL, Jungbluth A,
Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and
cancer. Nat Rev Cancer. 5:615–625. 2005.
|
|
24
|
De Plaen E, Arden K, Traversari C, Gaforio
JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B,
Lurquin C, et al: Structure, chromosomal localization, and
expression of 12 genes of the MAGE family. Immunogenetics.
40:360–369. 1994.
|
|
25
|
Rogner UC, Wilke K, Steck E, Korn B and
Poustka A: The melanoma antigen gene (MAGE) family is clustered in
the chromosomal band Xq28. Genomics. 29:725–731. 1995.
|
|
26
|
Li S, Shi X, Li J and Zhou X:
Pathogenicity of the MAGE family. Oncol Lett. 22:8442021.
|
|
27
|
van den Elsen GA, Tobben L, Ahmed AI,
Verkes RJ, Kramers C, Marijnissen RM, Olde Rikkert MG and van der
Marck MA: Effects of tetrahydrocannabinol on balance and gait in
patients with dementia: A randomised controlled crossover trial. J
Psychopharmacol. 31:184–191. 2017.
|
|
28
|
Kerkar SP, Wang ZF, Lasota J, Park T,
Patel K, Groh E, Rosenberg SA and Miettinen MM: MAGE-A is more
highly expressed than NY-ESO-1 in a systematic immunohistochemical
analysis of 3668 cases. J Immunother. 39:181–187. 2016.
|
|
29
|
Fon Tacer K, Montoya MC, Oatley MJ, Lord
T, Oatley JM, Klein J, Ravichandran R, Tillman H, Kim M, Connelly
JP, et al: MAGE cancer-testis antigens protect the mammalian
germline under environmental stress. Sci Adv. 5:eaav48322019.
|
|
30
|
Hao YH, Doyle JM, Ramanathan S, Gomez TS,
Jia D, Xu M, Chen ZJ, Billadeau DD, Rosen MK and Potts PR:
Regulation of WASH-dependent actin polymerization and protein
trafficking by ubiquitination. Cell. 152:1051–1064. 2013.
|
|
31
|
Liu S, Sang M, Xu Y, Gu L, Liu F and Shan
B: Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell
carcinoma and their prognostic significance: A retrospective
clinical study. Acta Otolaryngol. 136:506–513. 2016.
|
|
32
|
Hou SY, Sang MX, Geng CZ, Liu WH, Lü WH,
Xu YY and Shan BE: Expressions of MAGE-A9 and MAGE-A11 in breast
cancer and their expression mechanism. Arch Med Res. 45:44–51.
2014.
|
|
33
|
Guo L, Sang M, Liu Q, Fan X, Zhang X and
Shan B: The expression and clinical significance of
melanoma-associated antigen-A1, -A3 and -A11 in glioma. Oncol Lett.
6:55–62. 2013.
|
|
34
|
De Smet C, Loriot A and Boon T:
Promoter-dependent mechanism leading to selective hypomethylation
within the 5' region of gene MAGE-A1 in tumor cells. Mol Cell Biol.
24:4781–4790. 2004.
|
|
35
|
Wischnewski F, Pantel K and Schwarzenbach
H: Promoter demethylation and histone acetylation mediate gene
expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.
Mol Cancer Res. 4:339–349. 2006.
|
|
36
|
Laiseca JE, Ladelfa MF, Cotignola J, Peche
LY, Pascucci FA, Castaño BA, Galigniana MD, Schneider C and Monte
M: Functional interaction between co-expressed MAGE-A proteins.
PLoS One. 12:e01783702017.
|
|
37
|
Mahmoud AM: Cancer testis antigens as
immunogenic and oncogenic targets in breast cancer. Immunotherapy.
10:769–778. 2018.
|
|
38
|
Salmaninejad A, Zamani MR, Pourvahedi M,
Golchehre Z, Hosseini Bereshneh A and Rezaei N: Cancer/testis
antigens: Expression, regulation, tumor invasion, and use in
immunotherapy of cancers. Immunol Invest. 45:619–640. 2016.
|
|
39
|
Õunap K, Kurg K, Võsa L, Maiväli Ü, Teras
M, Planken A, Ustav M and Kurg R: Antibody response against
cancer-testis antigens MAGEA4 and MAGEA10 in patients with
melanoma. Oncol Lett. 16:211–218. 2018.
|
|
40
|
Djureinovic D, Dodig-Crnković T, Hellström
C, Holgersson G, Bergqvist M, Mattsson JSM, Pontén F, Ståhle E,
Schwenk JM and Micke P: Detection of autoantibodies against
cancer-testis antigens in non-small cell lung cancer. Lung Cancer.
125:157–163. 2018.
|
|
41
|
Mischo A, Kubuschok B, Ertan K, Preuss KD,
Romeike B, Regitz E, Schormann C, de Bruijn D, Wadle A, Neumann F,
et al: Prospective study on the expression of cancer testis genes
and antibody responses in 100 consecutive patients with primary
breast cancer. Int J Cancer. 118:696–703. 2006.
|
|
42
|
Zang C, Zhao Y, Qin L, Liu G, Sun J, Li K,
Zhao Y, Sheng S, Zhang H, He N, et al: Distinct tumour
antigen-specific T-cell immune response profiles at different
hepatocellular carcinoma stages. BMC Cancer. 21:10072021.
|
|
43
|
Connerotte T, Van Pel A, Godelaine D,
Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G and
Coulie PG: Functions of Anti-MAGE T-cells induced in melanoma
patients under different vaccination modalities. Cancer Res.
68:3931–3940. 2008.
|
|
44
|
Huang LQ, Brasseur F, Serrano A, De Plaen
E, van der Bruggen P, Boon T and Van Pel A: Cytolytic T lymphocytes
recognize an antigen encoded by MAGE-A10 on a human melanoma. J
Immunol. 162:6849–6854. 1999.
|
|
45
|
Gure AO, Chua R, Williamson B, Gonen M,
Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ and
Altorki NK: Cancer-testis genes are coordinately expressed and are
markers of poor outcome in non-small cell lung cancer. Clin Cancer
Res. 11:8055–8062. 2005.
|
|
46
|
Zhang S, Zhai X, Wang G, Feng J, Zhu H, Xu
L, Mao G and Huang J: High expression of MAGE-A9 in tumor and
stromal cells of non-small cell lung cancer was correlated with
patient poor survival. Int J Clin Exp Patho. 8:541–550. 2015.
|
|
47
|
Qi Y, Cao KX, Xing FC, Zhang CY, Huang Q,
Wu K, Wen FB, Zhao S and Li X: High expression of MAGE-A9 is
associated with unfavorable survival in esophageal squamous cell
carcinoma. Oncol Lett. 14:3415–3420. 2017.
|
|
48
|
Sang M, Wang L, Ding C, Zhou X, Wang B,
Wang L, Lian Y and Shan B: Melanoma-associated antigen genes-an
update. Cancer Lett. 302:85–90. 2011.
|
|
49
|
Doyle JM, Gao J, Wang J, Yang M and Potts
PR: MAGE-RING protein complexes comprise a family of E3 ubiquitin
ligases. Mol Cell. 39:963–974. 2010.
|
|
50
|
Xiao TZ, Suh Y and Longley BJ: MAGE
proteins regulate KRAB zinc finger transcription factors and KAP1
E3 ligase activity. Arch Biochem Biophys. 563:136–144. 2014.
|
|
51
|
Su S, Chen X, Geng J, Minges JT, Grossman
G and Wilson EM: Melanoma antigen-A11 regulates
substrate-specificity of Skp2-mediated protein degradation. Mol
Cell Endocrinol. 439:1–9. 2017.
|
|
52
|
Cui J, Wang L, Zhong W, Chen Z, Chen J,
Yang H and Liu G: Development and validation of epigenetic
signature predict survival for patients with laryngeal squamous
cell carcinoma. DNA Cell Biol. 40:247–264. 2021.
|
|
53
|
Cui J, Chen Y, Ou Y, Liu G, Wen Q, Zhu W,
Liang L, Chen Z, Yang H, Wang L and Wei M: Cancer germline antigen
gene MAGEB2 promotes cell invasion and correlates with immune
microenvironment and immunotherapeutic efficiency in laryngeal
cancer. Clin Immunol. 240:1090452022.
|
|
54
|
Klionsky DJ, Petroni G, Amaravadi RK,
Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cadwell K,
Cecconi F, Choi AMK, et al: Autophagy in major human diseases. EMBO
J. 40:e1088632021.
|
|
55
|
Ravichandran R, Kodali K, Peng J and Potts
PR: Regulation of MAGE-A3/6 by the CRL4-DCAF12 ubiquitin ligase and
nutrient availability. EMBO Rep. 20:e473522019.
|
|
56
|
Güre AO, Wei IJ, Old LJ and Chen YT: The
SSX gene family: Characterization of 9 complete genes. Int J
Cancer. 101:448–453. 2002.
|
|
57
|
Crew AJ, Clark J, Fisher C, Gill S, Grimer
R, Chand A, Shipley J, Gusterson BA and Cooper CS: Fusion of SYT to
two genes, SSX1 and SSX2, encoding proteins with homology to the
Kruppel-associated box in human synovial sarcoma. EMBO J.
14:2333–2340. 1995.
|
|
58
|
Skytting B, Nilsson G, Brodin B, Xie Y,
Lundeberg J, Uhlén M and Larsson O: A novel fusion gene, SYT-SSX4,
in synovial sarcoma. J Natl Cancer Inst. 91:974–975. 1999.
|
|
59
|
Feng X, Huang YL, Zhang Z, Wang N, Yao Q,
Pang LJ, Li F and Qi Y: The role of SYT-SSX fusion gene in
tumorigenesis of synovial sarcoma. Pathol Res Pract.
222:1534162021.
|
|
60
|
Fligman I, Lonardo F, Jhanwar SC, Gerald
WL, Woodruff J and Ladanyi M: Molecular diagnosis of synovial
sarcoma and characterization of a variant SYT-SSX2 fusion
transcript. Am J Pathol. 147:1592–1599. 1995.
|
|
61
|
dos Santos NR, Torensma R, de Vries TJ,
Schreurs MW, de Bruijn DR, Kater-Baats E, Ruiter DJ, Adema GJ, van
Muijen GN and van Kessel AG: Heterogeneous expression of the SSX
cancer/testis antigens in human melanoma lesions and cell lines.
Cancer Res. 60:1654–1662. 2000.
|
|
62
|
Lim FL, Soulez M, Koczan D, Thiesen HJ and
Knight JC: A KRAB-related domain and a novel transcription
repression domain in proteins encoded by SSX genes that are
disrupted in human sarcomas. Oncogene. 17:2013–2018. 1998.
|
|
63
|
dos Santos NR, de Bruijn DR, Kater-Baats
E, Otte AP and van Kessel AG: Delineation of the protein domains
responsible for SYT, SSX, and SYT-SSX nuclear localization. Exp
Cell Res. 256:192–202. 2000.
|
|
64
|
Cronwright G, Le Blanc K, Götherström C,
Darcy P, Ehnman M and Brodin B: Cancer/testis antigen expression in
human mesenchymal stem cells: Down-regulation of SSX impairs cell
migration and matrix metalloproteinase 2 expression. Cancer Res.
65:2207–2215. 2005.
|
|
65
|
Anderson WJ, Maclean FM, Acosta AM and
Hirsch MS: Expression of the C-terminal region of the SSX protein
is a useful diagnostic biomarker for spermatocytic tumour.
Histopathology. 79:700–707. 2021.
|
|
66
|
Johansen S and Gjerstorff MF: Interaction
between polycomb and SSX proteins in pericentromeric
heterochromatin function and its implication in cancer. Cells.
9:2262020.
|
|
67
|
Wei R, Dean DC, Thanindratarn P, Hornicek
FJ, Guo W and Duan ZF: Cancer testis antigens in sarcoma:
Expression, function and immunotherapeutic application. Cancer
Lett. 479:54–60. 2020.
|
|
68
|
Türeci O, Chen YT, Sahin U, Güre AO, Zwick
C, Villena C, Tsang S, Seitz G, Old LJ and Pfreundschuh M:
Expression of SSX genes in human tumors. Int J Cancer. 77:19–23.
1998.
|
|
69
|
Jones PA and Gonzalgo ML: Altered DNA
methylation and genome instability: A new pathway to cancer? Proc
Natl Acad Sci USA. 94:2103–2105. 1997.
|
|
70
|
Atanackovic D, Arfsten J, Cao Y, Gnjatic
S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C,
Dierlamm J, et al: Cancer-testis antigens are commonly expressed in
multiple myeloma and induce systemic immunity following allogeneic
stem cell transplantation. Blood. 109:1103–1112. 2007.
|
|
71
|
Neumann F, Kubuschok B, Ertan K, Schormann
C, Stevanovic S, Preuss KD, Schmidt W and Pfreundschuh M: A peptide
epitope derived from the cancer testis antigen HOM-MEL-40/SSX2
capable of inducing CD4+ and CD8+ T-cell as well as B-cell
responses. Cancer Immunol Immunother. 60:1333–1346. 2011.
|
|
72
|
Hasegawa K, Koizumi F, Noguchi Y, Hongo A,
Mizutani Y, Kodama J, Hiramatsu Y and Nakayama E: SSX expression in
gynecological cancers and antibody response in patients. Cancer
Immun. 4:162004.
|
|
73
|
Cheever MA, Allison JP, Ferris AS, Finn
OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL,
Weiner LM and Matrisian LM: The prioritization of cancer antigens:
A national cancer institute pilot project for the acceleration of
translational research. Clin Cancer Res. 15:5323–5337. 2009.
|
|
74
|
McBride MJ, Pulice JL, Beird HC, Ingram
DR, D'Avino AR, Shern JF, Charville GW, Hornick JL, Nakayama RT,
Garcia-Rivera EM, et al: The SS18-SSX fusion oncoprotein hijacks
BAF complex targeting and function to drive synovial sarcoma.
Cancer Cell. 33:1128–1141.e7. 2018.
|
|
75
|
Banito A, Li X, Laporte AN, Roe JS,
Sanchez-Vega F, Huang CH, Dancsok AR, Hatzi K, Chen CC,
Tschaharganeh DF, et al: The SS18-SSX oncoprotein hijacks
KDM2B-PRC1 1 to drive synovial sarcoma. Cancer Cell. 33:527–541.e8.
2018.
|
|
76
|
Déjardin J: Switching between epigenetic
states at pericentromeric heterochromatin. Trends Genet.
31:661–672. 2015.
|
|
77
|
Schwartz YB, Kahn TG, Nix DA, Li XY,
Bourgon R, Biggin M and Pirrotta V: Genome-wide analysis of
polycomb targets in drosophila melanogaster. Nat Genet. 38:700–705.
2006.
|
|
78
|
Barco R, Garcia CB and Eid JE: The
synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the
polycomb complex protein Bmi1. PLoS One. 4:e50602009.
|
|
79
|
Wang J, Wang H, Hou W, Liu H, Zou Y, Zhang
H, Hou L, McNutt MA and Zhang B: Subnuclear distribution of SSX
regulates its function. Mol Cell Biochem. 381:17–29. 2013.
|
|
80
|
Gjerstorff MF and Ditzel HJ: An overview
of the GAGE cancer/testis antigen family with the inclusion of
newly identified members. Tissue Antigens. 71:187–192. 2008.
|
|
81
|
Gjerstorff MF, Johansen LE, Nielsen O,
Kock K and Ditzel HJ: Restriction of GAGE protein expression to
subpopulations of cancer cells is independent of genotype and may
limit the use of GAGE proteins as targets for cancer immunotherapy.
Br J Cancer. 94:1864–1873. 2006.
|
|
82
|
Gjerstorff MF, Kock K, Nielsen O and
Ditzel HJ: MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen
expression during human gonadal development. Hum Reprod.
22:953–960. 2007.
|
|
83
|
Gordeeva O: Cancer-testis antigens: Unique
cancer stem cell biomarkers and targets for cancer therapy. Semin
Cancer Biol. 53:75–89. 2018.
|
|
84
|
Tabatabaei Yazdi SA, Safaei M, Gholamin M,
Abdollahi A, Nili F, Jabbari Nooghabi M, Anvari K and Mojarrad M:
Expression and prognostic significance of cancer/testis antigens,
MAGE-E1, GAGE, and SOX-6, in glioblastoma: An immunohistochemistry
evaluation. Iran J Pathol. 16:128–136. 2021.
|
|
85
|
Götte K, Usener D, Riedel F, Hörmann K,
Schadendorf D and Eichmüller S: Tumor-associated antigens as
possible targets for immune therapy in head and neck cancer:
Comparative mRNA expression analysis of RAGE and GAGE genes. Acta
Otolaryngol. 122:546–552. 2002.
|
|
86
|
Chao NX, Li LZ, Luo GR, Zhong WG, Huang
RS, Fan R and Zhao FL: Cancer-testis antigen GAGE-1 expression and
serum immunoreactivity in hepatocellular carcinoma. Niger J Clin
Pract. 21:1361–1367. 2018.
|
|
87
|
Zhang SQ, Zhou XL, Yu H and Yu YH:
Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian
cancer tissues and cell lines. BMC Cancer. 10:1632010.
|
|
88
|
Kutilin DS: Regulation of gene expression
of cancer/testis antigens in colorectal cancer patients. Mol Biol.
54:520–534. 2020.
|
|
89
|
Zhang R, Ma L, Li W, Zhou S and Xu S:
Diagnostic value of multiple tumor-associated autoantibodies in
lung cancer. Onco Targets Ther. 12:457–469. 2019.
|
|
90
|
Ghafouri-Fard S, Seifi-Alan M, Shamsi R
and Esfandiary A: Immunotherapy in multiple myeloma using
cancer-testis antigens. Iran J Cancer Prev. 8:e37552015.
|
|
91
|
Melo DH, Mamede RCM, Neder L, Silva WA Jr,
Barros-Filho MC, Kowalski LP, Pinto CAL, Zago MA, Figueiredo DLA
and Jungbluth AA: Expression of cancer/testis antigens MAGE-A,
MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.
Oncol Lett. 14:6485–6496. 2017.
|
|
92
|
Sun F, Chan E, Wu Z, Yang X, Marquez VE
and Yu Q: Combinatorial pharmacologic approaches target
EZH2-mediated gene repression in breast cancer cells. Mol Cancer
Ther. 8:3191–3202. 2009.
|
|
93
|
Bazhin AV, Wiedemann N, Schnölzer M,
Schadendorf D and Eichmüller SB: Expression of GAGE family proteins
in malignant melanoma. Cancer Lett. 251:258–267. 2007.
|
|
94
|
Gjerstorff MF, Rösner HI, Pedersen CB,
Greve KB, Schmidt S, Wilson KL, Mollenhauer J, Besir H, Poulsen FM,
Møllegaard NE and Ditzel HJ: GAGE cancer-germline antigens are
recruited to the nuclear envelope by germ cell-less (GCL). PLoS
One. 7:e458192012.
|
|
95
|
Kular RK, Yehiely F, Kotlo KU, Cilensek
ZM, Bedi R and Deiss LP: GAGE, an antiapoptotic protein binds and
modulates the expression of nucleophosmin/B23 and interferon
regulatory factor 1. J Interferon Cytokine Res. 29:645–655.
2009.
|
|
96
|
Nin DS, Wujanto C, Tan TZ, Lim D, Damen
JMA, Wu KY, Dai ZM, Lee ZW, Idres SB, Leong YH, et al: GAGE
mediates radio resistance in cervical cancers via the regulation of
chromatin accessibility. Cell Rep. 36:1096212021.
|
|
97
|
Zendman AJW, Van Kraats AA, Weidle UH,
Ruiter DJ and Van Muijen GN: The XAGE family of
cancer/testis-associated genes: alignment and expression profile in
normal tissues, melanoma lesions and Ewing's sarcoma. Int J Cancer.
99:361–369. 2002.
|
|
98
|
Xie C and Wang GM: XAGE-1b cancer/testis
antigen is a potential target for immunotherapy in prostate cancer.
Urol Int. 94:354–362. 2015.
|
|
99
|
Nakagawa K, Noguchi Y, Uenaka A, Sato S,
Okumura H, Tanaka M, Shimono M, Ali Eldib AM, Ono T, Ohara N, et
al: XAGE-1 expression in non-small cell lung cancer and antibody
response in patients. Clin Cancer Res. 11:5496–5503. 2005.
|
|
100
|
Pan Z, Tang B, Hou Z, Zhang J, Liu H, Yang
Y, Huang G, Yang Y and Zhou W: XAGE-1b expression is associated
with the diagnosis and early recurrence of hepatocellular
carcinoma. Mol Clin Oncol. 2:1155–1159. 2014.
|
|
101
|
Gong L, Peng J, Cui Z, Chen P, Han H,
Zhang D and Leng X: Hepatocellular carcinoma patients highly and
specifically expressing XAGE-1 exhibit prolonged survival. Oncol
Lett. 1:1083–1088. 2010.
|
|
102
|
Koizumi F, Noguchi Y, Saika T, Nakagawa K,
Sato S, Eldib AM, Nasu Y, Kumon H and Nakayama E: XAGE-1 mRNA
expression in prostate cancer and antibody response in patients.
Microbiol Immunol. 49:471–476. 2005.
|
|
103
|
Mori M, Funakoshi T, Kameyama K, Kawakami
Y, Sato E, Nakayama E, Amagai M and Tanese K: Lack of XAGE-1b and
NY-ESO-1 in metastatic lymph nodes may predict the potential
survival of stage III melanoma patients. J Dermatol. 44:671–680.
2017.
|
|
104
|
Tarek MM, Shafei AE, Ali MA and Mansour
MM: Computational prediction of vaccine potential epitopes and
3-dimensional structure of XAGE-1b for non-small cell lung cancer
immunotherapy. Biomed J. 41:118–128. 2018.
|
|
105
|
Talebian Yazdi M, Loof NM, Franken KL,
Taube C, Oostendorp J, Hiemstra PS, Welters MJ and van der Burg SH:
Local and systemic XAGE-1b-specific immunity in patients with lung
adenocarcinoma. Cancer Immunol Immunother. 64:1109–1121. 2015.
|
|
106
|
Zhou B, Li T, Liu Y and Zhu N: Preliminary
study on XAGE-1b gene and its mechanism for promoting tumor cell
growth. Biomed Rep. 1:567–572. 2013.
|
|
107
|
Brinkmann U, Vasmatzis G, Lee B,
Yerushalmi N, Essand M and Pastan I: PAGE-1, an X chromosome-linked
GAGE-like gene that is expressed in normal and neoplastic prostate,
testis, and uterus. Proc Natl Acad Sci USA. 95:10757–10762.
1998.
|
|
108
|
Kulkarni P, Dunker AK, Weninger K and
Orban J: Prostate-associated gene 4 (PAGE4), an intrinsically
disordered cancer/testis antigen, is a novel therapeutic target for
prostate cancer. Asian J Androl. 18:695–703. 2016.
|
|
109
|
Suyama T, Shiraishi T, Zeng Y, Yu W,
Parekh N, Vessella RL, Luo J, Getzenberg RH and Kulkarni P:
Expression of cancer/testis antigens in prostate cancer is
associated with disease progression. Prostate. 70:1778–1787.
2010.
|
|
110
|
Zeng Y, Gao D, Kim JJ, Shiraishi T, Terada
N, Kakehi Y, Kong C, Getzenberg RH and Kulkarni P:
Prostate-associated gene 4 (PAGE4) protects cells against stress by
elevating p21 and suppressing reactive oxygen species production.
Am J Clin Exp Urol. 1:39–52. 2013.
|
|
111
|
Yilmaz-Ozcan S, Sade A, Kucukkaraduman B,
Kaygusuz Y, Senses KM, Banerjee S and Gure AO: Epigenetic
mechanisms underlying the dynamic expression of cancer-testis
genes, PAGE2, -2B and SPANX-B, during mesenchymal-to-epithelial
transition. PLoS One. 9:e1079052014.
|
|
112
|
Hellman M, Tossavainen H, Rappu P, Heino J
and Permi P: Characterization of intrinsically disordered prostate
associated gene (PAGE5) at single residue resolution by NMR
spectroscopy. PLoS One. 6:e266332011.
|
|
113
|
Salgia R, Jolly MK, Dorff T, Lau C,
Weninger K, Orban J and Kulkarni P: Prostate-associated gene 4
(PAGE4): Leveraging the conformational dynamics of a dancing
protein cloud as a therapeutic target. J Clin Med. 7:1562018.
|
|
114
|
Uversky VN: Dancing protein clouds: The
strange biology and chaotic physics of intrinsically disordered
proteins. J Biol Chem. 291:6681–6688. 2016.
|
|
115
|
Monika FJ, Simon I, Friedrich P and Tompa
P: Preformed structural elements feature in partner recognition by
intrinsically unstructured proteins. Biophys J. 88:560a2005.
|
|
116
|
Sampson N, Ruiz C, Zenzmaier C, Bubendorf
L and Berger P: PAGE4 positivity is associated with attenuated AR
signaling and predicts patient survival in hormone-naive prostate
cancer. Am J Pathol. 181:1443–1454. 2012.
|
|
117
|
Lv C, Fu S, Dong Q, Yu Z, Zhang G, Kong C,
Fu C and Zeng Y: PAGE4 promotes prostate cancer cells survive under
oxidative stress through modulating MAPK/JNK/ERK pathway. J Exp
Clin Cancer Res. 38:242019.
|
|
118
|
Rajagopalan K, Qiu R, Mooney SM, Rao S,
Shiraishi T, Sacho E, Huang H, Shapiro E, Weninger KR and Kulkarni
P: The stress-response protein prostate-associated gene 4,
interacts with c-Jun and potentiates its transactivation. Biochim
Biophys Acta. 1842:154–163. 2014.
|
|
119
|
Tavakoli Koudehi A, Mahjoubi B, Mirzaei R,
Shabani S and Mahjoubi F: AKAP4, SPAG9 and NY-ESO-1 in Iranian
colorectal cancer patients as probable diagnostic and prognostic
biomarkers. Asian Pac J Cancer Prev. 19:463–469. 2018.
|
|
120
|
Chen YT, Scanlan MJ, Sahin U, Türeci O,
Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M and Old
LJ: A testicular antigen aberrantly expressed in human cancers
detected by autologous antibody screening. Proc Natl Acad Sci USA.
94:1914–1918. 1997.
|
|
121
|
Raza A, Merhi M, Inchakalody VP,
Krishnankutty R, Relecom A, Uddin S and Dermime S: Unleashing the
immune response to NY-ESO-1 cancer testis antigen as a potential
target for cancer immunotherapy. J Transl Med. 18:1402020.
|
|
122
|
Smith SM and Iwenofu OH: NY-ESO-1: A
promising cancer testis antigen for sarcoma immunotherapy and
diagnosis. Chin Clin Oncol. 7:442018.
|
|
123
|
Pollack SM: The potential of the CMB305
vaccine regimen to target NY-ESO-1 and improve outcomes for
synovial sarcoma and myxoid/round cell liposarcoma patients. Expert
Rev Vaccines. 17:107–114. 2018.
|
|
124
|
Jo U, Roh J, Song MJ, Cho KJ, Kim W and
Song JS: NY-ESO-1 as a diagnostic and prognostic marker for myxoid
liposarcoma. Am J Transl Res. 14:1268–1278. 2022.
|
|
125
|
Hashimoto K, Nishimura S, Ito T, Oka N,
Kakinoki R and Akagi M: Clinicopathological assessment of
cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma. Eur J
Histochem. 66:33772022.
|
|
126
|
Nagata Y, Kageyama S, Ishikawa T, Kokura
S, Okayama T, Abe T, Murakami M, Otsuka K, Ariyoshi T, Kojima T, et
al: Prognostic significance of NY-ESO-1 antigen and PIGR expression
in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as
adjuvant therapy. Cancer Immunol Immunother. 71:2743–2755.
2022.
|
|
127
|
Čeprnja T, Mrklić I, Perić Balja M,
Marušić Z, Blažićević V, Spagnoli GC, Juretić A, Čapkun V, Tečić
Vuger A, Vrdoljak E and Tomić S: Prognostic significance of
lymphocyte infiltrate localization in triple-negative breast
cancer. J Pers Med. 12:9412022.
|
|
128
|
Liu MY, Su H, Huang HL and Chen JQ: Cancer
stem-like cells with increased expression of NY-ESO-1 initiate
breast cancer metastasis. Oncol Lett. 18:3664–3672. 2019.
|
|
129
|
van Rhee F, Szmania SM, Zhan F, Gupta SK,
Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J
and Tricot G: NY-ESO-1 is highly expressed in poor-prognosis
multiple myeloma and induces spontaneous humoral and cellular
immune responses. Blood. 105:3939–3944. 2005.
|
|
130
|
Iura K, Kohashi K, Hotokebuchi Y, Ishii T,
Maekawa A, Yamada Y, Yamamoto H, Iwamoto Y and Oda Y: Cancer-testis
antigens PRAME and NY-ESO-1 correlate with tumour grade and poor
prognosis in myxoid liposarcoma. J Pathol Clin Res. 1:144–159.
2015.
|
|
131
|
Giavina-Bianchi M, Giavina-Bianchi P,
Sotto MN, Muzikansky A, Kalil J, Festa-Neto C and Duncan LM:
Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells
in cutaneous melanoma. J Immunol Res. 2015:7613782015.
|
|
132
|
Wang H, Chen D, Wang R, Quan W, Xia D, Mei
J, Xu J and Liu C: NY-ESO-1 expression in solid tumors predicts
prognosis: A systematic review and meta-analysis. Medicine
(Baltimore). 98:e179902019.
|
|
133
|
Gnjatic S, Nishikawa H, Jungbluth AA, Güre
AO, Ritter G, Jäger E, Knuth A, Chen YT and Old LJ: NY-ESO-1:
review of an immunogenic tumor antigen. Adv Cancer Res. 95:1–30.
2006.
|
|
134
|
Thomas R, Al-Khadairi G, Roelands J, et
al: NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Frontiers in immunology. 9:9472018.
|
|
135
|
Astaneh M, Dashti S and Esfahani ZT:
Humoral immune responses against cancer-testis antigens in human
malignancies. Hum Antibodies. 27:237–240. 2019.
|
|
136
|
Jäger E, Gnjatic S, Nagata Y, Stockert E,
Jäger D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, et
al: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and
antibody responses in peptide-vaccinated patients with NY-ESO-1+
cancers. Proc Natl Acad Sci USA. 97:12198–12203. 2000.
|
|
137
|
Jäger E, Nagata Y, Gnjatic S, Wada H,
Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jäger D, et
al: Monitoring CD8 T cell responses to NY-ESO-1: Correlation of
humoral and cellular immune responses. Proc Natl Acad Sci USA.
97:4760–4765. 2000.
|
|
138
|
Barrow C, Browning J, MacGregor D, Davis
ID, Sturrock S, Jungbluth AA and Cebon J: Tumor antigen expression
in melanoma varies according to antigen and stage. Clin Cancer Res.
12:764–771. 2006.
|
|
139
|
Li F, Zhao F, Li M, Pan M, Shi F, Xu H,
Zheng D, Wang L and Dou J: Decreasing New York esophageal squamous
cell carcinoma 1 expression inhibits multiple myeloma growth and
osteolytic lesions. J Cell Physiol. 235:2183–2194. 2020.
|
|
140
|
Wang H, Xia Y, Yu J, Guan H, Wu Z, Ban D
and Wang M: Expression of New York esophageal squamous cell
carcinoma 1 and its association with Foxp3 and
indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell
lung cancer. HLA. 94:39–48. 2019.
|
|
141
|
Ko TY, Kim JI and Lee SH: Relationship
between cancer stem cell marker CD133 and cancer germline antigen
genes in NCI-H292 lung cancer cells. Korean J Thorac Cardiovasc
Surg. 53:22–27. 2020.
|
|
142
|
Gong W, Hoffmann JM, Stock S, Wang L, Liu
Y, Schubert ML, Neuber B, Hückelhoven-Krauss A, Gern U, Schmitt A,
et al: Comparison of IL-2 vs IL-7/IL-15 for the generation of
NY-ESO-1-specific T cells. Cancer Immunol Immunother. 68:1195–1209.
2019.
|
|
143
|
Hirayama M, Tomita Y, Yuno A, Tsukamoto H,
Senju S, Imamura Y, Sayem MA, Irie A, Yoshitake Y, Fukuma D, et al:
An oncofetal antigen, IMP-3-derived long peptides induce immune
responses of both helper T cells and CTLs. Oncoimmunology.
5:e11233682016.
|
|
144
|
Hayashi R, Nagato T, Kumai T, Ohara K,
Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata
M, et al: Expression of placenta-specific 1 and its potential for
eliciting anti-tumor helper T-cell responses in head and neck
squamous cell carcinoma. Oncoimmunology. 10:18565452020.
|
|
145
|
Minhas V, Kumar R, Moitra T, Singh R,
Panda AK and Gupta SK: Immunogenicity and contraceptive efficacy of
recombinant fusion protein encompassing Sp17 spermatozoa-specific
protein and GnRH: Relevance of adjuvants and microparticles based
delivery to minimize number of injections. Am J Reprod Immunol.
83:e132182020.
|
|
146
|
Taheri-Anganeh M, Savardashtaki A, Vafadar
A, Movahedpour A, Shabaninejad Z, Maleksabet A, Amiri A, Ghasemi Y
and Irajie C: In silico design and evaluation of PRAME+FliCΔD2D3 as
a new breast cancer vaccine candidate. Iran J Med Sci. 46:52–60.
2021.
|
|
147
|
Matteo M, Greco P, Levi Setti PE, Morenghi
E, De Rosario F, Massenzio F, Albani E, Totaro P and Liso A:
Preliminary evidence for high anti-PLAC1 antibody levels in
infertile patients with repeated unexplained implantation failure.
Placenta. 34:335–339. 2013.
|
|
148
|
Fan C, Qu H, Wang X, Sobhani N, Wang L,
Liu S, Xiong W, Zeng Z and Li Y: Cancer/testis antigens: From
serology to mRNA cancer vaccine. Semin Cancer Biol. 76:218–231.
2021.
|
|
149
|
Kono K, Mizukami Y, Daigo Y, Takano A,
Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y and Fujii
H: Vaccination with multiple peptides derived from novel
cancer-testis antigens can induce specific T-cell responses and
clinical responses in advanced esophageal cancer. Cancer Sci.
100:1502–1509. 2009.
|
|
150
|
Lopes A, Vandermeulen G and Préat V:
Cancer DNA vaccines: Current preclinical and clinical developments
and future perspectives. J Exp Clin Cancer Res. 38:1462019.
|
|
151
|
Herrada AA, Rojas-Colonelli N,
González-Figueroa P, Roco J, Oyarce C, Ligtenberg MA and Lladser A:
Harnessing DNA-induced immune responses for improving cancer
vaccines. Hum Vaccin Immunother. 8:1682–1693. 2012.
|
|
152
|
Rezaei T, Davoudian E, Khalili S, Amini M,
Hejazi M, de la Guardia M and Mokhtarzadeh A: Strategies in DNA
vaccine for melanoma cancer. Pigment Cell Melanoma Res. 34:869–891.
2021.
|
|
153
|
Wu Y, Sang M, Liu F, Zhang J, Li W, Li Z,
Gu L, Zheng Y, Li J and Shan B: Epigenetic modulation combined with
PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11
antigen-specific CD8+T cells against esophageal carcinoma.
Carcinogenesis. 41:894–903. 2020.
|
|
154
|
Jahanafrooz Z, Baradaran B, Mosafer J,
Hashemzaei M, Rezaei T, Mokhtarzadeh A and Hamblin MR: Comparison
of DNA and mRNA vaccines against cancer. Drug Discov Today.
25:552–560. 2020.
|
|
155
|
Heine A, Juranek S and Brossart P:
Clinical and immunological effects of mRNA vaccines in malignant
diseases. Mol Cancer. 20:522021.
|
|
156
|
Sahin U, Muik A, Derhovanessian E, Vogler
I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, et
al: COVID-19 vaccine BNT162b1 elicits human antibody and
TH1 T cell responses. Nature. 586:594–599. 2020.
|
|
157
|
Liu W, Tang H, Li L, Wang X, Yu Z and Li
J: Peptide-based therapeutic cancer vaccine: Current trends in
clinical application. Cell Prolif. 54:e130252021.
|
|
158
|
Nelde A, Rammensee HG and Walz JS: The
peptide vaccine of the future. Mol Cell Proteomics.
20:1000222021.
|
|
159
|
Iinuma H, Fukushima R, Inaba T, Tamura J,
Inoue T, Ogawa E, Horikawa M, Ikeda Y, Matsutani N, Takeda K, et
al: Phase I clinical study of multiple epitope peptide vaccine
combined with chemoradiation therapy in esophageal cancer patients.
J Transl Med. 12:842014.
|
|
160
|
Kono K, Iinuma H, Akutsu Y, Tanaka H,
Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R,
et al: Multicenter, phase II clinical trial of cancer vaccination
for advanced esophageal cancer with three peptides derived from
novel cancer-testis antigens. J Transl Med. 10:1412012.
|
|
161
|
Schwartzentruber DJ, Lawson DH, Richards
JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K,
Pockaj B, et al: gp100 peptide vaccine and interleukin-2 in
patients with advanced melanoma. N Engl J Med. 364:2119–2127.
2011.
|
|
162
|
Suzuki H, Fukuhara M, Yamaura T, Mutoh S,
Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Osugi J, Hoshino M, et
al: Multiple therapeutic peptide vaccines consisting of combined
novel cancer testis antigens and anti-angiogenic peptides for
patients with non-small cell lung cancer. J Transl Med.
11:972013.
|
|
163
|
Kotsakis A, Papadimitraki E, Vetsika EK,
Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis
D and Georgoulias V: A phase II trial evaluating the clinical and
immunologic response of HLA-A2(+) non-small cell lung cancer
patients vaccinated with an hTERT cryptic peptide. Lung Cancer.
86:59–66. 2014.
|
|
164
|
Yoshitake Y, Fukuma D, Yuno A, Hirayama M,
Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y,
et al: Phase II clinical trial of multiple peptide vaccination for
advanced head and neck cancer patients revealed induction of immune
responses and improved OS. Clin Cancer Res. 21:312–321. 2015.
|
|
165
|
Okuyama R, Aruga A, Hatori T, Takeda K and
Yamamoto M: Immunological responses to a multi-peptide vaccine
targeting cancer-testis antigens and VEGFRs in advanced pancreatic
cancer patients. Oncoimmunology. 2:e270102013.
|
|
166
|
Smith HA, Rekoske BT and McNeel DG: DNA
vaccines encoding altered peptide ligands for SSX2 enhance
epitope-specific CD8+ T-cell immune responses. Vaccine.
32:1707–1715. 2014.
|
|
167
|
Li L and Petrovsky N: Molecular mechanisms
for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines.
15:313–329. 2016.
|
|
168
|
Duperret EK, Liu S, Paik M, Trautz A,
Stoltz R, Liu X, Ze K, Perales-Puchalt A, Reed C, Yan J, et al: A
designer cross-reactive DNA immunotherapeutic vaccine that targets
multiple MAGE-A family members simultaneously for cancer therapy.
Clin Cancer Res. 24:6015–6027. 2018.
|
|
169
|
Smith HA, Cronk RJ, Lang JM and McNeel DG:
Expression and immunotherapeutic targeting of the SSX family of
cancer-testis antigens in prostate cancer. Cancer Res.
71:6785–6795. 2011.
|
|
170
|
Smith HA and McNeel DG: Vaccines targeting
the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific
cytolytic T cells. J Immunother. 34:569–580. 2011.
|
|
171
|
Martínez-Puente DH, Pérez-Trujillo JJ,
Zavala-Flores LM, García-García A, Villanueva-Olivo A,
Rodríguez-Rocha H, Valdés J, Saucedo-Cárdenas O, Montes de Oca-Luna
R and Loera-Arias MJ: Plasmid DNA for therapeutic applications in
cancer. Pharmaceutics. 14:18612022.
|
|
172
|
Disis MLN, Guthrie KA, Liu Y, Coveler AL,
Higgins DM, Childs JS, Dang Y and Salazar LG: Safety and outcomes
of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in
patients with advanced-Stage ERBB2-positive breast cancer: A phase
1 nonrandomized clinical trial. JAMA Oncol. 9:71–78. 2023.
|
|
173
|
Huang X, Zhang G, Tang TY, Gao X and Liang
TB: Personalized pancreatic cancer therapy: From the perspective of
mRNA vaccine. Mil Med Res. 9:532022.
|
|
174
|
Rekoske BT, Smith HA, Olson BM, Maricque
BB and McNeel DG: PD-1 or PD-L1 blockade restores antitumor
efficacy following SSX2 epitope-modified DNA vaccine immunization.
Cancer Immunol Res. 3:946–955. 2015.
|
|
175
|
Sobhani N, Scaggiante B, Morris R, Chai D,
Catalano M, Tardiel-Cyril DR, Neeli P, Roviello G, Mondani G and Li
Y: Therapeutic cancer vaccines: From biological mechanisms and
engineering to ongoing clinical trials. Cancer Treat Rev.
109:1024292022.
|
|
176
|
Zhang R, Billingsley MM and Mitchell MJ:
Biomaterials for vaccine-based cancer immunotherapy. J Control
Release. 292:256–276. 2018.
|
|
177
|
Zhang C, Ma Y, Zhang J, Kuo JC, Zhang Z,
Xie H, Zhu J and Liu T: Modification of lipid-based nanoparticles:
An efficient delivery system for nucleic acid-based immunotherapy.
Molecules. 27:19432022.
|
|
178
|
Papachristofilou A, Hipp MM, Klinkhardt U,
Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G,
et al: Phase Ib evaluation of a self-adjuvanted protamine
formulated mRNA-based active cancer immunotherapy, BI1361849
(CV9202), combined with local radiation treatment in patients with
stage IV non-small cell lung cancer. J Immunother Cancer.
7:382019.
|
|
179
|
Sahin U, Oehm P, Derhovanessian E,
Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D,
Kuhn AN, Omokoko T, et al: An RNA vaccine drives immunity in
checkpoint-inhibitor-treated melanoma. Nature. 585:107–112.
2020.
|
|
180
|
Van Hoecke L, Verbeke R, Dewitte H,
Lentacker I, Vermaelen K, Breckpot K and Van Lint S: mRNA in cancer
immunotherapy: Beyond a source of antigen. Mol Cancer.
20:482021.
|
|
181
|
Chen J, Chen J and Xu Q: Current
developments and challenges of mRNA vaccines. Annu Rev Biomed Eng.
24:85–109. 2022.
|
|
182
|
He Q, Gao H, Tan D, Zhang H and Wang JZ:
mRNA cancer vaccines: Advances, trends and challenges. Acta Pharm
Sin B. 12:2969–2989. 2022.
|
|
183
|
Palmer CD, Rappaport AR, Davis MJ, Hart
MG, Scallan CD, Hong SJ, Gitlin L, Kraemer LD, Kounlavouth S, Yang
A, et al: Individualized, heterologous chimpanzee adenovirus and
self-amplifying mRNA neoantigen vaccine for advanced metastatic
solid tumors: Phase 1 trial interim results. Nat Med. 28:1619–1629.
2022.
|
|
184
|
Lorentzen CL, Haanen JB, Met Ö and Svane
IM: Clinical advances and ongoing trials on mRNA vaccines for
cancer treatment. Lancet Oncol. 23:e450–e458. 2022.
|
|
185
|
Roy DG, Geoffroy K, Marguerie M, Khan ST,
Martin NT, Kmiecik J, Bobbala D, Aitken AS, de Souza CT, Stephenson
KB, et al: Adjuvant oncolytic virotherapy for personalized
anti-cancer vaccination. Nat Commun. 12:26262021.
|
|
186
|
Duan LJ, Wang Q, Zhang C, Yang DX and
Zhang XY: Potentialities and challenges of mRNA vaccine in cancer
immunotherapy. Front Immunol. 13:236472022.
|
|
187
|
Slingluff CL Jr, Petroni GR, Olson WC,
Smolkin ME, Chianese-Bullock KA, Mauldin IS, Smith KT, Deacon DH,
Varhegyi NE, Donnelly SB, et al: A randomized pilot trial testing
the safety and immunologic effects of a MAGE-A3 protein plus AS15
immunostimulant administered into muscle or into
dermal/subcutaneous sites. Cancer Immunol Immunother. 65:25–36.
2016.
|
|
188
|
Abd-Aziz N and Poh CL: Development of
peptide-based vaccines for cancer. J Oncol. 2022:97493632022.
|
|
189
|
Bae J, Parayath N, Ma W, Amiji M, Munshi N
and Anderson KC: BCMA peptide-engineered nanoparticles enhance
induction and function of antigen-specific CD8+
cytotoxic T lymphocytes against multiple myeloma: Clinical
applications. Leukemia. 34:19712020.
|
|
190
|
Kruit WH, Suciu S, Dreno B, Mortier L,
Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ,
et al: Selection of immunostimulant AS15 for active immunization
with MAGE-A3 protein: Results of a randomized phase II study of the
European organisation for research and treatment of cancer melanoma
group in metastatic melanoma. J Clin Oncol. 31:2413–2420. 2013.
|
|
191
|
Goepfert PA, Tomaras GD, Horton H,
Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault
L, Vandepapeliere P, et al: Durable HIV-1 antibody and T-cell
responses elicited by an adjuvanted multi-protein recombinant
vaccine in uninfected human volunteers. Vaccine. 25:510–518.
2007.
|
|
192
|
Du G and Sun X: Engineering
nanoparticulate vaccines for enhancing antigen cross-presentation.
Curr Opin Biotechnol. 66:113–122. 2020.
|
|
193
|
Warrier VU, Makandar AI, Garg M, Sethi G,
Kant R, Pal JK, Yuba E and Gupta RK: Engineering anti-cancer
nanovaccine based on antigen cross-presentation. Biosci Rep.
39:BSR201932202019.
|
|
194
|
Miyamoto A, Honjo T, Masui M, Kinoshita R,
Kumon H, Kakimi K and Futami J: Engineering cancer/testis antigens
with reversible S-cationization to evaluate antigen spreading.
Front Oncol. 12:8693932022.
|
|
195
|
Zhang Y, Lin S, Wang XY and Zhu G:
Nanovaccines for cancer immunotherapy. Wiley Interdiscip Rev
Nanomed Nanobiotechnol. 11:e15592019.
|
|
196
|
Wen R, Umeano AC, Kou Y, Xu J and Farooqi
AA: Nanoparticle systems for cancer vaccine. Nanomedicine (Lond).
14:627–648. 2019.
|
|
197
|
Yang J, Li ZH, Zhou JJ, Chen RF, Cheng LZ,
Zhou QB and Yang LQ: Preparation and antitumor effects of
nanovaccines with MAGE-3 peptides in transplanted gastric cancer in
mice. Chin J Cancer. 29:359–364. 2010.
|
|
198
|
Somaiah N, Block MS, Kim JW, Shapiro GI,
Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen JH, et al:
First-in-class, first-in-human study evaluating LV305, a
dendritic-cell tropic lentiviral vector, in sarcoma and other solid
tumors expressing NY-ESO-1. Clin Cancer Res. 25:5808–5817.
2019.
|
|
199
|
Deng Z, Tian Y, Song J, An G and Yang P:
mRNA vaccines: The dawn of a new era of cancer immunotherapy. Front
Immunol. 13:8871252022.
|
|
200
|
Chen W, Wu Y, Deng J, Yang Z, Chen J, Tan
Q, Guo M and Jin Y: Phospholipid-membrane-based nanovesicles acting
as vaccines for tumor immunotherapy: Classification, mechanisms and
applications. Pharmaceutics. 14:24462022.
|
|
201
|
Wadman M: Public needs to prep for vaccine
side effects. Science. 370:10222020.
|
|
202
|
Kudo K, Miki Y, Carreras J, Nakayama S,
Nakamoto Y, Ito M, Nagashima E, Yamamoto K, Higuchi H, Morita SY,
et al: Secreted phospholipase A2 modifies extracellular
vesicles and accelerates B cell lymphoma. Cell Metab.
34:615–633.e8. 2022.
|
|
203
|
Cheng Y, Jiao X, Fan W, Yang Z, Wen Y and
Chen X: Controllable synthesis of versatile mesoporous organosilica
nanoparticles as precision cancer theranostics. Biomaterials.
256:1201912020.
|
|
204
|
Li J, Lu W, Yang Y, Xiang R, Ling Y, Yu C
and Zhou Y: Hybrid nanomaterials for cancer immunotherapy. Adv Sci
(Weinh). 10:e22049322023.
|
